Abstract 123: An Assessment of the Effects of Nebivolol, Carvedilol and Irbesartan on Left Ventricular Hypertrophy Due to Hypertension
The aim of this study is to research if the new generation beta-blockers (BB), carvedilol (C) and nebivolol (N), are as effective as irbesartan (I) on left ventricular hypertrophy (LVH) and to research whether or not there is a difference between C and N treatments.
Method: This study is a clinical, prospective and cohort study. The study included 85 patients (mean age:56.6±9.6 years) with stages 1 or 2 hypertension and LVH who didn’t receive antihypertensive. Three different treatment groups [I (n=28), N (n=25) and C (n=32)] were assessed clinically and echocardiographically 3, 6 and 12 months after the initial treatment. Devereux formula was used in the measurement of left ventricular mass (LVM). LVM index (LVMI) ≥125 g/m2 in male and ≥110g/m2 in female was accepted as LVH.
Results: There was no significant difference among treatment groups according to the initial LVMI and blood pressures (BP). Both between I and N groups and between I and C groups, there was a significant difference in the measurements of 12th month (p<0.05) while there wasn’t a significant difference in 3rd and 6th months according to LVMI. There was no significant difference between N and C groups (Figure). While the decrease of values in systolic and diastolic BPs were significant in all treatment groups at 3, 6 and 12 months after beginning (p<0.001), there was no significant difference among treatment groups.
Conclusions: This study shows that both of the new generation BBs can be more effective than irbesartan in the regression of LVH due to hypertension. However, there is no significant difference between N and C treatments. Still, the results should be supported by other prospective and randomized studies.
- © 2012 by American Heart Association, Inc.